{
    "Trade/Device Name(s)": [
        "Access Ostase"
    ],
    "Submitter Information": "Beckman Coulter, Inc.",
    "510(k) Number": "K232904",
    "Predicate Device Reference 510(k) Number(s)": [
        "K994278"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CIN"
    ],
    "Summary Letter Date": "April 15, 2024",
    "Summary Letter Received Date": "March 1, 2024",
    "Submission Date": "March 1, 2024",
    "Regulation Number(s)": [
        "21 CFR 862.1050"
    ],
    "Regulation Name(s)": [
        "Alkaline phosphatase or isoenzymes test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Bone alkaline phosphatase (BAP)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "DxI 9000 Access Immunoassay Analyzer",
        "Access Immunoassay Systems"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay",
        "Immunoenzymatic assay"
    ],
    "Methodologies": [
        "One-step sandwich immunoenzymatic assay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator",
        "Quality control material",
        "Wash solution",
        "Substrate"
    ],
    "Document Summary": "FDA 510(k) summary for Beckman Coulter Access Ostase chemiluminescent immunoassay to measure bone alkaline phosphatase on DxI 9000 Access Immunoassay Analyzer",
    "Indications for Use Summary": "A paramagnetic particle, chemiluminescent immunoassay for quantitative measurement of bone alkaline phosphatase (BAP) in serum and plasma, used as an aid in management of postmenopausal osteoporosis and Paget's disease",
    "fda_folder": "Clinical Chemistry"
}